Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Melanoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 3Panobinostat 2Cyclophosphamide 2Bevacizumab 2ribociclib 1marizomib 1dipinacoline glutamate 1cemiplimab 1Topotecan 1TIC10 compound 1Re-Irradiation 1Radiotherapy 1Radiation 1Maintenance 1Irinotecan 1Imiquimod 1Granulocyte-Macrophage Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Drug Tolerance 1Doxorubicin 1Diphtheria-Tetanus Vaccine 1Congresses as Topic 1Cilengitide 1Cetuximab 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diffuse Intrinsic Pontine Glioma × Maintenance × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡